About BioCopy
BioCopy is a company based in Basel (Switzerland) founded in 2018 by Niko Bausch and Gunter Roth. BioCopy offers products and services including Drug Discovery Platform, Antibody Engineering, and Precision Screening. BioCopy operates in a competitive market with competitors including BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
- Headquarter Basel, Switzerland
- Founders Niko Bausch, Gunter Roth
- SectorsHealthcare
- Email••••••••
- Website biocopy.com
- Social LinkedIn
- Legal Name Biocopy Ag
- Latest Funding Round$58.01 K (USD), Grant
Sep 2018
- InvestorsEuropean Union
& 1 more
Products & Services of BioCopy
BioCopy offers a comprehensive portfolio of products and services, including Drug Discovery Platform, Antibody Engineering, and Precision Screening.
AI-based system for matching biotherapeutics to cancer cells.
Automated platform for developing next-generation biotherapeutics.
Tool for speeding up risk assessment in drug discovery.
Funding Insights of BioCopy
- Total Rounds 2
- Last Round Grant — $58,006
- First Round $58,340
(Jun 2018)
- Investors Count 2
All 2 funding rounds of BioCopy with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | $58,006 | Grant | – | – | |
| Jun 2018 | $58,340 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in BioCopy
BioCopy has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for BioCopy
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioCopy
3 people are tracked at BioCopy (3 in leadership).
| Name | Role | Group |
|---|---|---|
Niko Bausch | Co-Founder | Leadership |
Gunter Roth | Co-Founder & Co-CEO | Leadership |
Matthias Wiedenfels | Co-CEO | Leadership |
Complete people profiles for BioCopy
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioCopy
3 dated milestones of BioCopy, from founding to its latest funding, stage changes and deals.
- Founded BioCopy is founded.
- Funding First funding round of $58K.
- Funding Latest funding round, Grant, of $58K.
Competitors of BioCopy
BioCopy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172.0M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.8B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| alxoncology.com | 2015 | Burlingame, United States | $123.0M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| strandtx.com | 2017 | Cambridge, United States | $103.1M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| poseida.com | 2015 | San Diego, United States | $323.8M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| annexonbio.com | 2011 | San Francisco, United States | $256.0M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| celgene.com | 1986 | Summit, United States | $45.0M | 4,891 | Therapies for cancer and inflammatory diseases are developed. |
Detailed competitors of BioCopy
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biocopy
Complete news archive for BioCopy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to BioCopy
10 companies that operate in the same segment as BioCopy (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioCopy
BioCopy was founded in 2018.
BioCopy is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Gunter Roth is the current CEO of BioCopy. They have also founded this company.
BioCopy was founded in 2018 in Basel, Switzerland, within the biotechnology sector. Immunotherapies targeting tumors and autoimmune diseases are developed through drug discovery processes. State-of-the-art microarray technology is employed to expedite immunoprofiling and the screening of T-cell receptors against various antigen-HLA complexes. Operations focus on immuno-oncological therapeutics to address unmet needs in oncology and autoimmunity.
BioCopy's top competitors include Moderna, BeiGene and Strand Therapeutics.
BioCopy offers Drug Discovery Platform, Antibody Engineering, and Precision Screening.
BioCopy has 2 investors. Key investors include European Union, and EIC Fund.
BioCopy operates through Biocopy Ag.